Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
|
|
MERRIMACK PHARMACEUTICALS INC (MACK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
SC 13D/A
| Western Standard LLC reports a 13.9% stake in Merrimack Pharmaceuticals, Inc. |
| 12/02/2020 |
SC 13D/A
| Newtyn Management, LLC reports a 11.4% stake in Merrimack Pharmaceuticals, Inc. |
| 07/24/2020 |
SC 13D/A
| Newtyn Management, LLC reports a 10.3% stake in Merrimack Pharmaceuticals, Inc. |
| 07/23/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/19/2019 |
SC 13D/A
| JFL Capital Management, LLC reports a 5.3% stake in Merrimack Pharmaceuticals, Inc. |
| 09/24/2019 |
SC 13D/A
| JFL Capital Management, LLC reports a 9.4% stake in Merrimack Pharmaceuticals, Inc. |
| 07/24/2019 |
SC 13D/A
| JFL Capital Management, LLC reports a 9.4% stake in Merrimack Pharmaceuticals, Inc. |
| 04/17/2019 |
SC 13D/A
| JFL Capital Management, LLC reports a 9.3% stake in Merrimack Pharmaceuticals, Inc. |
| 03/14/2019 |
SC 13D/A
| JFL Capital Management, LLC reports a 8.7% stake in Merrimack Pharmaceuticals, Inc. |
| 12/19/2018 |
SC 13D/A
| JFL Capital Management, LLC reports a 8.5% stake in Merrimack Pharmaceuticals, Inc. |
|
|